Cobimetinib - Genentech

Drug Profile

Cobimetinib - Genentech

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 07 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Breast cancer; Head and neck cancer; Histiocytosis; Renal cell carcinoma; Urogenital cancer
  • Phase I/II Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 31 Jul 2018 Roche initiates a phase II trial for Melanoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain (EudraCT2018-000759-41)
  • 26 Jul 2018 Discontinued - Phase-I for Solid tumours (Combination therapy with atezolizumab, Late-stage disease) in USA, Singapore, South Korea, Germany, Canada, Australia (PO) (NCT01988896) (Roche pipeline, July 2018)
  • 26 Jul 2018 Discontinued - Phase-III for Colorectal cancer (Combination therapy with atezolizumab, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Australia, Belgium, Hong Kong, Italy, South Korea, Poland, Russia, Spain, United Kingdom, Canada (IV) (NCT02788279) (Roche pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top